A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
Price : $35 *
At a glance
- Drugs Ixazomib (Primary) ; Vorinostat
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 31 Aug 2018 Biomarkers information updated
- 20 Mar 2018 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 16 Mar 2017 Status changed from recruiting to active, no longer recruiting.